Dossier assessment

Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-56
Last updated

Report documents

  1. Extract of dossier assessment

    Concizumab (haemophilia B) Benefit assessment according to §35a SGB V

    published on
    Document type
    PDF document, 491 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-56_en
  2. Dossier assessment

    Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 948 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-56

Dossier assessment

Indication:

Routine prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency) and factor IX inhibitors and of 12 years of age or more

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2025-10-16 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-56
Commission
Commission awarded on 29.04.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-56_en

Connected Projects

  1. Dossier assessment

    Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-55
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-124
    Last updated

    Status: Commission completed

  3. Addendum

    Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56

    Project no.
    G25-27
    Last updated

    Status: Commission completed

  4. Addendum

    Concizumab (haemophilia B) – Addendum to Project A25-56

    Project no.
    A25-115
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-123
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form